The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete. | |||||||||||||||||||||
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 13F FORM 13F INFORMATION TABLE |
|
COLUMN 1 | COLUMN 2 | COLUMN 3 | COLUMN 4 | COLUMN 5 | COLUMN 6 | COLUMN 7 | COLUMN 8 | ||||
VALUE | SHRS OR | SH/ | PUT/ | INVESTMENT | OTHER | VOTING AUTHORITY | |||||
NAME OF ISSUER | TITLE OF CLASS | CUSIP | (x$1000) | PRN AMT | PRN | CALL | DISCRETION | MANAGER | SOLE | SHARED | NONE |
Alexza Pharmaceuticals Inc | COM | 015384100 | 166 | 71,212 | SH | SOLE | 71,212 | 0 | 0 | ||
Anacor Pharmaceuticals Inc | COM | 032420101 | 28,837 | 1,178,474 | SH | SOLE | 1,178,474 | 0 | 0 | ||
Avalanche Biotechnologies Inc | COM | 05337G107 | 33,260 | 1,102,735 | SH | SOLE | 1,102,735 | 0 | 0 | ||
Avalanche Biotechnologies Inc | COM | 05337G107 | 9,573 | 280,000 | SH | DFND | 280,000 | 0 | 0 | ||
BioCryst Pharmaceuticals Inc | COM | 09058V103 | 17,060 | 1,744,356 | SH | SOLE | 1,744,356 | 0 | 0 | ||
DBV Technologies | COM | F2927N109 | 19,809 | 425,000 | SH | SOLE | 425,000 | 0 | 0 | ||
DBV Technologies | COM | F2927N109 | 6,525 | 140,000 | SH | DFND | 140,000 | 0 | 0 | ||
Dyax Corp | COM | 26746E103 | 20,249 | 2,000,859 | SH | SOLE | 2,000,859 | 0 | 0 | ||
Flamel Technologies S.A. | COM | 338488109 | 7,155 | 500,000 | SH | SOLE | 500,000 | 0 | 0 | ||
GW Pharmaceuticals | COM | 36197T103 | 25,213 | 311,853 | SH | SOLE | 311,853 | 0 | 0 | ||
Heron Therapeutics Inc | COM | 427746102 | 9,127 | 1,095,734 | SH | SOLE | 1,095,734 | 0 | 0 | ||
Lipocine Inc | COM | 53630X104 | 4,093 | 669,921 | SH | SOLE | 669,921 | 0 | 0 | ||
Neurocrine Biosciences Inc | COM | 64125C109 | 4,756 | 303,503 | SH | SOLE | 303,503 | 0 | 0 | ||
Ocera Therapeutics | COM | 67552A108 | 3,448 | 703,730 | SH | SOLE | 703,730 | 0 | 0 | ||
OHR Pharmaceutical | COM | 67778H200 | 3,458 | 477,000 | SH | SOLE | 477,000 | 0 | 0 | ||
Radius Health Inc | COM | 750469108 | 11,025 | 525,000 | SH | SOLE | 525,000 | 0 | 0 | ||
Stemline Therapeutics Inc | COM | 85858C107 | 265 | 21,300 | SH | SOLE | 21,300 | 0 | 0 | ||
Stemline Therapeutics Inc | COM | 85858C107 | 619 | 49,700 | SH | DFND | 49,700 | 0 | 0 | ||
TherapeuticsMD Inc | COM | 88338N107 | 3,928 | 846,500 | SH | SOLE | 846,500 | 0 | 0 | ||
Zafgen Inc | COM | 98885E103 | 10,024 | 541,480 | SH | SOLE | 541,480 | 0 | 0 | ||
ZS Pharma Inc | COM | 98979G105 | 3,923 | 100,000 | SH | SOLE | 100,000 | 0 | 0 |